Results 201 to 210 of about 87,711 (271)

Successful Management of Tumor Lysis Syndrome Following Enfortumab Vedotin Plus Pembrolizumab Therapy in Metastatic Urothelial Carcinoma: A Case Report. [PDF]

IJU Case Rep
Takemori D, Shigehisa R, Shimasaki S, Yamashita E, Kurano Y, Atagi K, Ota Y, Yamamoto S, Osakabe H, Nao T, Shimamoto T, Fukuhara H, Shimizu N, Fukata S, Ashida S, Inoue K.   +15 more
europepmc   +1 more source

Sorafenib Restores Pentose Phosphate Pathway‐Related Redox Homeostasis via the c‐Raf/HSP90/G6PD Axis in Hepatic Ischemia‐Reperfusion Injury

MedComm, Volume 7, Issue 7, July 2026.
Proposed mechanism of middle‐dose sorafenib modulates redox homeostasis via c‐Raf/HSP90/G6PD axis to attenuate hepatic IRI. This study demonstrates that middle‐dose sorafenib mitigates hepatic IRI through the c‐Raf/HSP90/G6PD axis to enhance pentose phosphate pathway‐mediated antioxidant defense and redox homeostasis, thereby alleviating inflammatory ...
Fengqiang Gao, Libin Dong, Yawen Tan, Zhen Zhang, Shengjun Xu, Zijian Lou, Yichao Wu, Siyu Chen, Li Zhuang, Zhengxing Lian, Shusen Zheng, Nasha Qiu, Kai Wang, Xiao Xu   +13 more
wiley   +1 more source

Recurrent Spontaneous Tumor Lysis Syndrome in Undiagnosed Follicular T-Cell Lymphoma. [PDF]

Case Rep Oncol
Sultan FH, Jindal PK, Sultan ZH, Bansal NR, Qiu S.   +4 more
europepmc   +1 more source

Ischemia–Reperfusion Injury: Molecular Mechanisms and Therapeutic Interventions

MedComm, Volume 7, Issue 7, July 2026.
Multiorgan ischemia–reperfusion injury begins with ischemia‐induced ATP depletion and ionic imbalance, followed by reperfusion‐triggered mitochondrial ROS/RNS bursts, regulated cell death, and DAMP release. Sterile inflammation converges on endothelial–immune–coagulation crosstalk, where NETs drive immunothrombosis, no‐reflow, and remote organ injury ...
Peng An, Yi An, Mengwei Chen, Longlong Wu, Rong Wang   +4 more
wiley   +1 more source

Case Report: Tumor lysis syndrome in advanced, massive hepatocellular carcinoma with main portal vein invasion following atezolizumab plus bevacizumab therapy. [PDF]

Front Oncol
Chou TS, Wu CF, Lin CL, Hsu CW.
europepmc   +1 more source

Initial Dose Tarlatamab–Associated Tumour Lysis Syndrome in Small Cell Lung Cancer: A Case Report

Respirology Case Reports, Volume 14, Issue 7, July 2026.
We report a fatal case of acute TLS following a single 1‐mg dose of tarlatamab in a patient with relapsed SCLC with extensive liver metastases. This case highlights the importance of TLS risk assessment prior to tarlatamab treatment. Extensive liver metastases and elevated lactate dehydrogenase levels may be risk factors for TLS in patients with SCLC ...
Katsuhiko Shibata, Hiromu Tanaka, Yusuke Arai, Yusuke Watanuki, Takashi Kokubo, Yo Watanabe, Shingo Nakayama, Takahiro Asami, Takashi Inoue   +8 more
wiley   +1 more source

Spontaneous Tumor Lysis Syndrome in a Thoracic Burkitt Lymphoma: A Case Report. [PDF]

Cureus
Figueiredo A, Pimentel J, Figueira M, Neves A.   +3 more
europepmc   +1 more source

An Aging Clock Based on Immune Repertoire Features: COVID‐19 Accelerates Aging

Aging Cell, Volume 25, Issue 7, July 2026.
We systematically profiled TCR/BCR repertoires in Chinese individuals and paired COVID‐19 samples, revealed aging‐driven remodeling and COVID‐accelerated immune senescence, and built a reliable immune repertoire aging clock for immune senescence evaluation.
Xin Gao, Si‐Jia Li, Jin Li, Zi‐Hui Wang, Lv‐Tao Zeng, Ya‐Qing Ma, Ya‐Min Dang, Ying‐Min Zhang, Hong‐Lei Liu, Li‐Qun Zhang, Jing Pang, Ju Cui, Tie‐Mei Zhang, Jian‐Ping Cai   +13 more
wiley   +1 more source

Hyperkalemia Versus Pseudohyperkalemia Without ECG Changes in Acute Blast Crisis Progressing to Tumor Lysis Syndrome. [PDF]

Cureus
Chaudhri M, Samad A, Lipschutz J, Iglesias J.   +3 more
europepmc   +1 more source

Benzbromarone as a Novel Candidate for Preventing Alzheimer's Disease: Evidence From Real‐World Data Screening and in Vitro Validation

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
Drug repositioning analysis identifies candidate therapeutic agents for Alzheimer’s diseaseand supports further mechanistic and translational investigation. ABSTRACT Drug development for Alzheimer's disease (AD) remains challenging, with only a 0.4% success rate from Phase I trials to regulatory approval.
Sho Sakagami, Yuya Yoshida, Shota Uemura, Taisei Kumamoto, Ryotaro Tsukamoto, Takumi Nishi, Shimpei Kawano, Kohei Fukuoka, Hanami Ino, Kengo Hamamura, Shigehiro Ohdo, Naoya Matsunaga   +11 more
wiley   +1 more source